PERK Inhibition Mitigates Restenosis and Thrombosis: A Potential Low-Thrombogenic Antirestenotic Paradigm

Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bowen, Zhang, Mengxue, Urabe, Go, Huang, Yitao, Chen, Guojun, Wheeler, Debra, Dornbos, David J., Huttinger, Allyson, Nimjee, Shahid M., Gong, Shaoqin, Guo, Lian-Wang, Kent, K. Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091514/
https://www.ncbi.nlm.nih.gov/pubmed/32215348
http://dx.doi.org/10.1016/j.jacbts.2019.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091514/
https://www.ncbi.nlm.nih.gov/pubmed/32215348
http://dx.doi.org/10.1016/j.jacbts.2019.12.005

Ejemplares similares